| Biomarker ID | 1997 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation status of RASGRF2 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Methylated in Clinical recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Clinical recurrence vs. biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | clinical recurrence (n = 80) versus biochemical recurrence (n = 43) |
| Senstivity | Training: 66.1 (52.6–77.9); validation: 75.4 (50.9–91.3) |
| Specificity | Training: 69.2 (52.4–82.9); validation:60.3 (36.0–80.8) |
| AUC | Training: 0.69; validation: 0.76 |
| Accuracy | NA |
| Level Of Significance | <0.0015 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | RASGRF2 |